The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs
- 169 Downloads
Acyloxyalkyl ester prodrugs of histone deacetylase inhibitors, a family of anti-cancer agents, are metabolized intracellularly to acids and aldehyde(s). The purpose of this study was to assess the in vitro and in vivo anticancer activity, selectivity and oral bioavailability of these prodrugs. The prodrugs exhibited a hierarchal potency of AN-193 ≥ AN-7 > AN-1 and AN-9 ≫ AN-10 against murine lung carcinoma (3LLD122) and human breast carcinoma (MCF-7) cell lines. AN-9, and to even greater extent AN-7, displayed preferential cytotoxicity against leukemic and glioblastoma cells compared to their normal cellular counterparts-normal mononuclear and astrocytes cells, respectively. In vivo, anti-metastatic activity was evaluated in a metastatic model of lung cancer in which Lewis lung carcinoma (3LLD122) cells are injected intravenously into C57/BL mice and produce lung nodules. The prodrugs administered orally demonstrated a significant inhibition of lung-lesion formation and their hierarchal potency concurred with that observed in vitro, with the exception of AN-193 that was the least active compound. Escalating doses of AN-7 (5–100 mg/kg), administered by oral or intraperitoneal routes and displayed equivalent anti-metastatic activities, confirmed the good oral bioavailability of AN-7. Consistent with these findings, a time course study of histone acetylation in subcutaneously implanted 3LL122 tumors showed 2–4 fold increases in histone acetylation within 0.5 h of intravenous, intraperitoneal, or oral administration of AN-7 (100 mg/kg). Relative contributions of the prodrug metabolites to the anti-neoplastic activity and the best candidate for clinical studies are discussed.
KeywordsAN-1 AN-7 AN-9 Histone acetylation Formaldehyde Lewis lung carcinoma
histone deacetylase inhibitors
structure activity relationships
Unable to display preview. Download preview PDF.
- 5.Zimra Y, Nudelman A, Zhuk R, Rabizadeh E, Shaklai M, Aviram A, Rephaeli A (2000) Uptake of acyloxyalkyl ester prodrugs of butyric acid into leukemic cells and their intracellular esterase-catalyzed hydrolysis. J Cancer Res Clin Oncol 123:152–160Google Scholar
- 9.Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone F, Eckhardt GS (2002) A Phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res 8:2142–2148PubMedGoogle Scholar
- 10.Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F, Bhatnagar A (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45:381–386PubMedCrossRefGoogle Scholar
- 12.Nudelman A, Gnizi E, Katz Y, Azulai R, Cohen-Ohana M, Zhuk R, Sampson SR, Langzam L, Fibach E, Prus E, Pugach V, Rephaeli A (2001) Prodrugs of butyric acid (III). Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur J Med Chem 36:63–74PubMedCrossRefGoogle Scholar
- 13.Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, Phillips DR, Malik Z, Nudelman A(2005) In vivo and in vitro anti tumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, on human prostate cancer. Int J Cancer 116:226–235PubMedCrossRefGoogle Scholar
- 15.Entin-Meer M, Rephaeli A, Yang X, Nudelman A, VandenBerg SR, Haas-Kogan DA: Butyric acid prodrugs are histone deacetylase inhibitors that demonstrate anti neoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Canc Ther (in press)Google Scholar
- 17.Coradini D, Pellizzaro C, Abolafio G, Bosco M, Scarlata I, Cantoni S, Stucchi L, Zorzet S, Turrin C, Sava G, Perbellini A, Daidone MG (2004) Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study. Invest New Drugs 22:207–217PubMedCrossRefGoogle Scholar
- 19.Kelly WK, O’Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923–3931PubMedCrossRefGoogle Scholar